1.
Arch. cardiol. Méx
; 92(3): 420-422, jul.-sep. 2022. graf
Artigo
em Inglês
|
LILACS-Express
| LILACS
| ID: biblio-1393843
2.
Arch Cardiol Mex
; 92(3): 420-422, 2022 07 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34491248
3.
J Pediatr Hematol Oncol
; 43(3): e448-e451, 2021 04 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32079989
RESUMO
Kawasaki disease (KD) is an acute systemic vasculitis of unknown etiology. KD can be complicated with macrophage activation syndrome. The optimal treatment for this KD complication has not been established, and a variety of treatments have been used. Infliximab, a chimeric monoclonal antibody that binds tumor necrosis factor, has proved to be efficacious in IV gammaglobulin resistant KD. We present 2 cases of KD complicated with macrophage activation syndrome, including 1 patient with DiGeorge syndrome successfully treated with a combined treatment of IV gammaglobulin, corticosteroids, cyclosporine, and infliximab.